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1. Introduction
M. tuberculosis and M. leprae are intracellular pathogens. M. tuberculosis can survive up to
decades in a phenotypically non-replicating dormant state, primarily in hypoxic granulomas
in the lung [1]. The otherwise drug-susceptible dormant mycobacteria show the remarkable
property to develop drug resistance within the granulomas of the host. These nonreplicative
drug-resistant bacteria within the host´s tissues are called persisters [2].
Mycobacteria have outstanding mechanisms to escape from elimination and have a high
degree of intrinsic resistance to most antibiotics, chemotherapeutic agents and immune
eradication [3,4]. One major obstacle for host defence mechanisms and therapeutic interven‐
tion is the robust, mycolic acid-rich cell wall, which is unique among prokaryotes [3,5]. In the
last years it has become apparent that mycobacteria induce the accumulation of lipids in the
host cells and use them as energy and carbon source. This strategy is regarded as another
crucial factor for the long term-survival of M. tuberculosis and M. leprae in the host. Most
mycobacteria have the ability to synthesize lipid bodies as reservoirs for fatty acids. The lipid
droplet- containing macrophages are called “foamy macrophages” and are the hallmark of M.
tuberculosis and M. leprae infection.
M. leprae is the causative agent of leprosy. Leprosy is a chronic infectious disease caused by
the obligate intracellular bacterium Mycobacterium leprae and is a major source of morbidity in
developing countries [6,7]. Leprosy patients show two major manifestations of the disease,
known as as lepromatous leprosy (LL), and tuberculoid leprosy (TT) [6]. TT is observed in
patients with good T-cell mediated (Th1) immunity and is characterized by granuloma
formation and death of Schwann cells (Scs) leading to myelin degradation and nerve destruc‐
tion [8,9]. Patients with poor T-cell mediated immunity show the lepromatous type leprosy
(LL), which leads to a high bacterial load inside host cells specially in Schwann cells and
macrophages [8,10-12]. For both forms of leprosy damage of the nerves is observed [12].
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Lepromatous leprosy lesions of the skin, eyes, nerves, and lymph nodes are characterized by
tumor-like accumulations of foamy macrophages. The foamy macrophages are fully packed
with lipid droplets (LDs) and contain high numbers of leprosy bacilli. These aggregations of
foamy macrophages expand slowly and disfigure the body of the host [13].
The finding that M. leprae has insufficient fatty acid synthetase activity to support growth lead
to the hypothesis that M. leprae scavenges lipids from the host cell [14]. Over the last years it
has become evident that survival and persistence of M. tuberculosis is critically dependent on
lipid body formation. Furthermore lipid body formation seems to be the prerequisite for
transition of M. tuberculosis to the dormant state. The formation of foamy macrophages is a
process which appears to be a key event in both sustaining persistent bacteria and release of
infectious bacilli [15]. This goes along with the important observation that sputum from
tuberculosis patients contains lipid body-laden bacilli [16,17].
In the dormant state lipids from lipid bodies appear to be the primary carbon source for M.
tuberculosis in vivo. For M. tuberculosis several bacterial genes are upregulated during the
dormant state and have been reported to be involved in lipid metabolism such as diacylglycerol
acyltransferase (tgs1), lipase (lipY), and isocitrate lyase (icl) [18,19].
M. leprae has a small genome (3.2 Mb). The obligate intracellular organism shows a moderate
genome degradation and several genes are absent when compared with other mycobacterial
species. Due to the gene loss M. leprae is strongly dependent on the host for basic metabolic
functions [8,20]. Macrophages infected with M. leprae contain oxidized host lipids and it has
been observed that M. leprae upregulates 13 host lipid metabolism genes in T-lep lesions and
26 in L-lep lesions. The oxidized lipids inhibit innate immune responses and thus seem to be
an important virulence factor for the organism [21].
This review highlights the importance of the LDs as one of the most unique determinant for
persistence and virulence of M. tuberculosis and M. leprae. The formation of LDs in M. tubercu‐
losis and M. leprae in infected host cells shall be compared and the lipid metabolism of both
organisms will be discussed.
In this review we will use the term “lipid droplets” for lipid-rich inclusions in the host and
“lipid bodies” for lipid-rich inclusions in the pathogen.
2. Biogenesis of lipid inclusions in bacteria and eukaryotes
The current models of lipid droplet biogenesis are still hypothetical and have been reviewed
extensively by Murphy in 1999 and Ohsaki in 2009 [22,23]. The most common model supposes
that the membrane protein diacyltransferase DGAT1 synthesizes triacylglycerols (TAG),
which accumulate between the two membrane leaflets of the endoplasmic reticulum (ER) to
be finally released by budding. The lipids are covered by a phospholipid monolayer from the
ER membrane.
The formation of lipid bodies in bacteria has been even less characterized. Wältermann et al.
suggested in 2005 that a bifunctional wax ester synthase/acyl-CoA:diacylglycerol acyltrans‐
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ferase, (WS/DGAT) synthesizes TAG for lipid body formation. WS/DGAT is an integral
membrane protein and synthesizes a growing globule around the cytoplasmic portion of the
enzyme. Finally the lipid body is released to the cytoplasm. The origin of the surface phos‐
pholipid monolayer is not known [22,24].
2.1. Lipid droplets in the host
The accumulation of lipid droplets occurs also in several infectious, and inflammatory
conditions, including in atherosclerosis [25], bacterial sepsis [26], viral infections [27], and in
mycobacterial infections [15,28,29]. M. tuberculosis infected macrophages store mostly neutral
lipids, while cells infected with M. leprae seem to accumulate next to TAG a high degree of
cholesterol and cholesterol esters [10,30].
LDs are observed in various cells of the immune system including macrophages, neutrophils,
and eosinophils. The structure and composition of LDs is highly conserved. They contain a
core of neutral lipid esters typically TAG, but also sterols and sterol esters [31-36]. The surface
is covered by a phospholipid monolayer, which is composed at least in some cells by unique
fatty acids [37].
M. leprae infects preferentially macrophages and Schwann cells [11]. A typical feature of
lepromatous leprosy is the survival and replication of. M. leprae within the lipid droplets stored
in the enlarged phagosome of histiocytes. Lipid droplets are thought to be an important
nutrient source for the bacillus. A major concern in leprosy is peripheral neuropathy. The
damage to nerves of the peripheral nervous system is caused by the the infection of Schwann
cells (SCs) by M. leprae. In LL nerve biopsies, highly infected SCs also contain lipid droplets
and show a foamy appearance, such as Virchow cells found in dermal lesions [38]. The biology
of the these foamy cells has been characterized poorly until now. Neither the origin or nature
of the lipids has been elucidated yet. Only recently it in vitro studies by Mattos could show
that ML induces the formation of lipid droplets in human SCs [10]. Moreover, the group found
that LDs are promptly recruited to bacterial phagosomes. In SCs LD recruiting by bacterial
phagosomes depends on cytoskeletal reorganization and PI3K signaling, but is independent
of TLR2 bacterial sensing [10].
Important markers for the lipid accumulation in adipocytes or macrophages are lipid-droplet-
associated proteins such as adipose differentiation-related protein ADRP and perilipin, which
play essential roles in lipid-droplet formation [39]. After phagocytosis of live M. leprae ADRP
expression is constantly upregulated in human monocytes. ADRP and perilipin are localized
at the phagosomal membrane (Figure 4) [39].
2.2. Lipid bodies in the pathogen
Prokaryotes do not generally produce lipid bodies containing TAG. Accumulation of TAG
in intracellular lipid-bodies is mostly restricted to bacteria belonging to the actinomycetes
group [40].
Most mycobacterial species accumulate considerable amounts of TAG during infection
[24,41-44]. The intracellular pathogen M. tuberculosis can survive up to decades in a pheno‐
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typically non-replicating dormant state, primarily in hypoxic granulomas in the lung [1]. The
otherwise drug-susceptible dormant bacteria develop drug resistance within the granulomas
of the host. These nonreplicative drug-resistant bacteria within the host´s tissues are called
persisters [2].
It has been observed that persisters store large amounts of intracellular triacylglycerol lipid
bodies (LBs) [15,17,28,45,46]. M. tuberculosis uses TAG from the lipid bodies as energy and
carbon source under conditions such as starvation [47], oxygen depletion [48], and pathogen
reactivation [49]. The observation that sputum from tuberculosis patients contains lipid body-
laden bacilli, proves the importance of lipids for the survival of the bacterium in the host [17].
3. M. tuberculosis induces foamy macrophages in the host
M. tuberculosis infects primarily alveolar macrophages, which reside within alveoli. The
infected macrophage leaves the alveoli and migrates then towards the next lung draining
lymph node. M. tuberculosis inhibits the generation of the phagolysosome and the bacteria
begin to multiply within the macrophage [50]. The host’s immune response seems to be unable
to clear the bacillus from the infected macrophages. Infected macrophages secrete TNF-α and
chemokines, which recruit systemic monocytes. The macrophages start to enlarge and
accumulate TAG in lipid droplets. These lipid-filled foamy macrophages (FM) are surrounded
by an outer layer of lymphocytes. Within the foamy macrophages the bacteria resist in
phagosomes, packed with lipid droplets.
Over the last years it has become evident that survival and persistence of M. tuberculosis is
critically dependent on lipid body formation, and induction of foamy macrophages appears
to be a key event in both sustaining persistent bacteria and and release of infectious bacilli [15].
M. tuberculosis-infected phagosomes engulf cellular lipid droplets and finally the bacteria are
completely enclosed by cellular lipid droplets. Only enclosed by lipid droplets the bacteria
form lipid bodies and cell replication comes to a halt and finally the bacteria enter the state of
dormancy and induced drug resistance [19,28]. In the nonreplicative state M. tuberculosis
induces several bacterial genes involved in lipid metabolism such as diacylglycerol acyltrans‐
ferase (tgs1), such as diacylglycerol acyltransferase (tgs1), lipase (lipY), and isocitrate lyase (icl)
are upregulated [19,46]. In conclusion lipid body formation seems to be absolutely necessary
for transition of M. tuberculosis to the dormant state. This goes along with the important
observation that sputum from tuberculosis patients contains lipid body-laden bacilli [17].
The final granuloma consists of a core of infected, lipid-laden macrophages, which are
surrounded by an outer layer of additional differentiated macrophages. The outer shell
consists of T lymphocytes, B lymphocytes, dendritic cells, neutrophils, fibroblasts and an
extracellular matrix [29,51-53].
The development and composition of a human tuberculosis granuloma is depicted in Figure 1.
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Figure 1. Development and structure of the human tuberculosis granuloma. 1, Uptake of M. tuberculosis by alveolar
macrophages. 2, Migration of the infected macrophage towards the next lung draining lymph node. 3, Recruitment of
systemic monocytes. 4, Granuloma formation. L, Lymphocytes at the periphery of the granuloma outside the fibrous
outer layer. F, Fibrous capsule. Contains fibroblasts, collagen and other extracellular matrix proteins. M, Macrophage
region with foamy macrophages. C, Caseum. Contains debris and lipids from necrotic macrophages. Orange, Lipid
droplets of the macrophage. Yellow dots, Lipid bodies.
3.1. Lipid body formation in M. tuberculosis is critically dependent on lipid droplets from
the host
Host lipids from lipid droplets are used by the pathogen as substantial nutrient source.
Middlebrook already demonstrated in the late 1940s that mycobacterial growth in vitro was
enhanced by supplementation with oleic acid [54]. Over the last years several groups have
reported that M. tuberculosis within foamy macrophages produces lipid bodies, suggesting that
they are able to accumulate host cell lipids [19,55]. Mycobacterial growth inside adipocytes is
strictly dependent upon TAG provided by lipid droplets in host cells [55], and it has been
shown that M. tuberculosis incorporates intact host TAG into bacterial TAG [46].
The utilization of host lipids in vivo does not only promote survival but may also increases
virulence and modulate the immune response to infection. Growth of M. tuberculosis on fatty
acids such as such propionate or valerate during infection leads to increased production of the
surface-exposed lipid virulence factors, phthiocerol dimycocerosate (PDIM) and sulfolipid-1
(SL-1) [56].
Cholesterol utilization was also identified to be required for mycobacterial persistence [57]. In
2008 Pandey and Sassetti found that M. tuberculosis can grow using cholesterol as a primary
carbon source and that the mce4 transporter is required for cholesterol uptake. M. tuberculo‐
sis contains four homologous mce operons, mce1–mce4, which are thought to encode lipid
transporters [57,58].
Especially M. leprae infected macrophages show an increased accumulation of cholesterol and
cholesterol [10,30]. But in contrast to M. tuberculosis the M. leprae genome encodes only one
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operon for cholesterol uptake (mce1). All M. leprae five mce genes were overexpressed during
intracellular growth in mouse and human biopsies [59,60]. This observation suggests, that the
intracellular bacilli population induces cholersterol uptake of the infected cell and subse‐
quently uses the stored cholesterol as carbon and energy source.
Cholesterol is also essential for uptake of M. tuberculosis and M. leprae in macrophages.
Cholesterol accumulates at the site of mycobacterial entry in macrophages and promotes
mycobacterial uptake. Cholesterol mediates the recruitment of TACO from the plasma
membrane to the phagosome [61]. TACO, also termed as CORO1A, is a coat protein that
prevents phagosome-lysosome fusion and thus degradation of mycobacteria in phagolyso‐
somes (Figure 4) [61,62]. This mechanism for the formation of TACO-coated phagosomes
promotes intracellular survival [62,63].
3.2. Lipid body formation in M. tuberculosis is critically dependent on lipid droplets
Host lipids from lipid droplets are used by the pathogen as substantial nutrient source.
Middlebrook already demonstrated in the late 1940s that mycobacterial growth in vitro was
enhanced by supplementation with oleic acid [54]. Host lipids play an important role during
infection. They appear to be the primary carbon source for M. tuberculosis in vivo. Over the last
years several groups have reported that M. tuberculosis within foamy macrophages produces
lipid bodies, suggesting that they are able to accumulate host cell lipids [19,55]. Neyrolles et
al. showed that mycobacterial growth inside adipocytes occurs only after the formation of lipid
droplets in the host cell. This result emphasizes that M. tuberculosis is dependent upon TAG
provided by lipid droplets in host cells [55]. In 2011 Daniel et al. finally demonstrated that M.
tuberculosis inside foamy macrophages imports fatty acids derived from host TAG and
incorporates them intact into bacterial TAG. Moreover the group proved the accumulation of
TAG in lipid bodies [46].
The utilization of host lipids in vivo does not only promote survival but may also increases
virulence and modulate the immune response to infection. Growth of M. tuberculosis on fatty
acids such as such propionate or valerate during infection leads to increased production of the
surface-exposed lipid virulence factors, phthiocerol dimycocerosate (PDIM) and sulfolipid-1
(SL-1) [56].
Cholesterol utilization was also identified to be required for mycobacterial persistence [57]. In
2008 Pandey and Sassetti found that M. tuberculosis can grow using cholesterol as a primary
carbon source and that the mce4 transporter is required for cholesterol uptake. M. tuberculo‐
sis contains four homologous mce operons, mce1–mce4, which are thought to encode lipid
transporters [57,58].
3.3. Biosynthesis of TAG and formation of lipid bodies in M. tuberculosis
Biosynthesis of TAG consists of the sequential esterification of the glycerol moiety with fatty
acyl-residues by various acyltransferases. Fatty acid biosynthesis consists of the stepwise
addition of acetyl groups, which are provided by acetyl-CoA. The initial step is the transfer of
an acetyl group from acetyl-CoA to a small protein, called acyl carrier protein (ACP). In the
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following two-carbon fragments are added sequentially to yield fatty acids of the desired
length. M. tuberculosis uses both type I and type II FAS systems for fatty acid elongation. The
multifunctional FAS I enzyme (Rv2524c) catalyzes the de novo synthesis of C16- and C18-S-ACP.
These fatty acids are converted to the CoA derivative and used primarily for the synthesis of
membrane phospholipids. By continuous elongation of these fatty acids FAS I produces
specifically the C20- and C26-S-ACP products, and these fatty acids are released as the CoA
derivatives. The C20 fatty acid is transferred to the FAS II system for the synthesis of the very-
long-chain mero segment of α-, methoxy-, and ketomycolic acids [64]. The transfer from the
FAS I to the FAS II system occurs by a key condensing enzyme, the ketoacyl ACP synthase III
(FabH). FabH catalyzes the decarboxylative condensation of malonyl-ACP with the acyl-CoA
products of the FAS I system (Figure 2). Two distinct cyclopropane synthases, MmaA2 and
PcaA introduce cyclopropane rings into the the growing acyl chain [64-66].
Figure 2. Fatty acid biosynthesis in Mycobacterium tuberculosis. The FAS-II elongation module uses the substrates R-
CO-S-ACP and malonyl-S-ACP derived from malonyl-S-CoA, generated by FabD. FabH condenses both substrates R,
long-chain alkyl group. Enzymes involved in these reactions are as follows: FabG1, a β-ketoacyl-ACP reductase catalyz‐
es the reduction of beta-ketoacyl-ACP substrates to beta-hydroxyacyl-ACP. β-hydroxyacyl-ACP dehydrase. 2-trans-eno‐
yl-ACP reductase (InhA). The β-ketoacyl-ACP synthase (KasA/KasB) catalyzes the addition of of two carbons from
malonyl-ACP to R-CO-S-ACP (See text for details). R, long-chain alkyl group. ACP, acyl carrier protein. Enzymes are in
bold letters. Selected inhibitors are depicted in red bold letters. TLM, thiolactomycin. CER, cerulenin. ETH, ethionamide.
INH, isoniazid. TRC, triclosan. TAC, thiacetazone.
Esterification  of  fatty  acids  with  glycerol-3-phosphate  occurs  via  sequential  acylation  of
the sn-1,2 and 3 positions of glycerol-3-phosphate,  and removal of the phosphate group
before the last acylation step. The terminal reaction is the esterification of diacylglycerol
(DAG) with acyl-CoA by an diacylglycerol  acyltransferase  [40].  Animals  and plants  use
diacylglycerol acyl‐transferases (DGAT) for the terminal esterification. DGATs catalyze ex‐
clusively  the  esterification  of  acyl-CoA  with  diacylglycerol.  Bacteria  do  not  contain
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DGATs but only bifunctional wax ester synthase/acyl-CoA:diacylglycerol acyltransferases
(WS/DGAT). WS/DGATs, mediate next to TAG formation the synthesis of waxes by ester‐
ification of acyl-CoA with alcohol [67]. The genome of M. tuberculosis  codes for 15 genes
which contain the highly conserved putative active site motif of WS/DGATs (HHxxxDG).
These genes were designated as “tgs”, triacylglycerol synthases, but have only a weak se‐
quence similarity to other WS/DGAT sequences. All 15 expressed mycobacterial Tgs pro‐
teins show diacylglycerol acyltransferase activity and Tgs1 has the highest activity of all
enzymes [48].  Gene disruption of  tgs1  results  in  a  drastic  reduction of  major  C26 long-
chain fatty acid in M. tuberculosis grown under hypoxic conditions. Thus Tgs1 appears to
be a major contributor to TAG synthesis in M. tuberculosis  so far [48,68].  And moreover
two homologous proteins to Tgs1 and Tgs2 (BCG3153c and BCG3794c) and another poor‐
ly characterized acyltransferase (BCG1489c) were found to be exclusively associated to lip‐
id  bodies.  The  disruption  of  BCG3153c,  BCG3794c,  and  BCG1489c  reduces  TAG
accumulation  during  the  hypoxia-induced  nonreplicating  state,  revealing  that  the  en‐
zymes are involved in TAG synthesis during latency and pathogenicity [69].
Ten of the 15 tgs genes in M. tuberculosis are located adjacent or proximal to 11 lip genes that
are annotated as probable phospholipases or lipases-esterases-carboxylesterases. Some tgs
genes may be cotranscribed with neighboring lip genes and may synthesize triacylglycerols
from the released fatty acids from the host [18]. Lip gene products may be important for
utilization of TAGs during dormancy and upon reactivation after dormancy. The tgs gene
Rv0221 is located near lipC (Rv0220), lipW (Rv0217c), acyl-CoA synthetase (Rv0214), acyl-CoA
dehydrogenase (Rv0215c), and an integral membrane acyltransferase (Rv0228). This clustering
of genes of the fatty acid metabolism suggests that these genes may be cotranscribed and may
release fatty acid from host TAG, carry out the transport of fatty acids and finally catalyze the
re-synthesis of TAGs in the pathogen. Rv0221 and LipC have to be shown to be catalytical
active. [18,70].
In summary Tgs enzymes play a major role in TAG synthesis, lipid body formation and
maintenance.
Ag85A, a mycoltransferase, that is known to catalyze the formation of the cord factor was
recently found to have additional DGAT activity [71]. The kinetic parameters are quite similar
to those reported for the M. tuberculosis Tgs1-4, but the primary sequence of Ag85A does not
contain the active site motif of WS/DGATs or TGS enzymes (HHxxxDG) [48,68,71]. Ag85A
belongs to the α/β hydrolase fold family and contains the consensus GXSXG sequence. The
enzyme is a carboxylesterase with an additional acyltransferase activity. Overexpression of
Ag85A induces lipid body formation in M. smegmatis. The enzyme is located in the mycobac‐
terial cell wall, suggesting that it may be involved in the maintenance of lipid droplets in the
host cell [71].
The genome of M.leprae  contains also mycolytransferase 85 complex genes (A, B and C).
Transcripts of these genes are upregulated either in infected nude mouse or human skin
lesions [59].
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The M. leprae genome shows only one predicted gene product which has has a significant
degree of identity to any the Tgs enzymes from M. tuberculosis [18]. The tgs gene product
ML1244 shows 72% identity to Rv2484c from M. tuberculosis. Rv2448 is located next to a
carboxylesterase lipQ, (Rv2485c), a probable glycerol-3-phosphate acyltransferase, (Rv2482c),
a lysophosphatidic acid acyltransferase-like protein (Rv2483c), and a probable enoyl-CoA
hydratase (Rv2486). The gene cluster of lipid metabolism genes suggests a possible involve‐
ment of the gene products in the synthesis of TAG [18]. A few tgs genes (Rv3234c, Rv3233c,
Rv2285, and Rv1425) are located proximal to lipoproteins, which may serve as donors or
acceptors of fatty acids [48]
3.4. Activation of TAG – Lipases and esterases of M. tuberculosis
Neutral lipids in the core of the lipid body are hydrolyzed by lipases or esterases, yielding
fatty acids for energy generation and anabolism of membrane phospholipids.
In the genome of M. tuberculosis  H37Rv twenty-one genes are termed as putative lipases
(lip A to W, except K and S) [72]. The annotation was only based on the presence of the
consensus sequence GXSXG, which is characteristic for the large group of the α/β hydro‐
lase fold protein family, which includes lipases as well as esterases, proteases, peroxidas‐
es, epoxide hydrolases and dehalogenases [72]. Thus the members of the lip group have
only a very low level of sequence identity of ~20% and might have another function apart
from lipid hydrolysis. Only the gene product of Rv3097c (LipY)) shows reasonable hydro‐
lase activity for long-chain TAG with chain lengths ranging from C4 to C18. Overexpres‐
sion of LipY induces extensive TAG hydrolysis. Disruption of lipY markedly reduces but
does  not  completely  inactivate  TAG hydrolase  activity,  which  suggests  the  presence  of
other lipases in M. tuberculosis [47,49].
Overexpression of LipY in M. bovis Bacillus Calmette-Guérin reduces protection against
infection in mice, indicating that lipY plays a central role in TAG hydrolysis and virulence
[47,73,74]. LipY contains a PE (Pro-Glu) domain, that is involved in modulation of LipY activity
[73]. The PE domain contains a signal sequence for secretion of LipY by the ESX-5 system. It
has been implicated that the secreted LipY is loosely associated with the bacterial surface where
it may hydrolyze host’s TAG [75].
Several other esterases, next to the members of the Lip group have been identified and
biochemically characterized. They all belong also to the α/β hydrolase fold family and showing
the minimal GXSXG motif. In 2007 Côtes et al. characterized a novel lipase Rv0183. The enzyme
is only found in the cell wall and culture medium. This observation suggests that Rv0183 is
involved in the degradation of the host cell lipids e.g. when M. tuberculosis infects adipocytes
[55,76]. Another probably cell wall-associated carboxylesterase is encoded by Rv2224c. The
esterase Rv2224c was found to be required for bacterial survival in mice [77]. The substrate
spectrum of Rv2224c is poorly characterized and until now it is unknown whether the enzyme
uses TAG as substrate [77]. Furthermore the three-dimensional structures of the esterases
Rv0045c (PDB 3P2M) [78], Rv1847 (PDB 3S4K), and LipW (3QH4) from M. tuberculosis have
been determined, but unfortunately it is not known whether these enzymes are involved in
TAG hydrolysis.
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3.5. Lipase genes of M. leprae
In the M. leprae genome only 2 lipase genes (lipG, lipU) were found. But M. tuberculosis has also
only six expressed Lip enzymes, showing reasonable hydrolase activity for long-chain
triacylglycerols. (LipY, LipC, LipL, LipX, LipK, LipG). LipG and LipU from M. leprae are
homologous with LipG and LipU from M. tuberculosis and show sequence identities of 72 and
79%, respectively. The lipases LipG and LipU from M. tuberculosis show very low and no
activity with long chain triacylglycerols as substrates [47]. M. tuberculosis LipY is suspected to
be a major functional lipase, which utilizes stored triacylglycerols (TAG) during dormancy
and reactivation of the pathogen [47,49]. LipY shows only a weak similarity with M. leprae
LipU (23 % identity). In summary it appears that M. leprae uses different lipases for the
hydrolysis of fatty acids than M. tuberculosis.
3.6. Enzymes of the β-oxidation and glyoxylate cycle
M. tuberculosis can grow on fatty acids as sole carbon source and it has been demonstrat‐
ed that fatty acid oxidation is important for survival of the pathogen in the lungs of mice
[79,80]. Fatty acids are oxidized via the β-oxidation cycle and the glyoxylate shunt, to re‐
plenish TCA cycle intermediates during growth [81]. The β-oxidation cycle consists of five
biochemical reactions, where one molecule acetyl-CoA of the fatty acid is split off per cy‐
cle. The genome of M. tuberculosis encodes around 100 genes, designated as fad genes (fat‐
ty acid degradation) with putative roles in the β-oxidation of fatty acids. While E. coli has
only one enzyme for each step of the β-oxidation cycle, M. tuberculosis seems to have sev‐
eral  backup enzymes for each reaction [82].  The initial  step of β-oxidation is  the forma‐
tion  of  acyl-CoA from free  fatty  acids  and  Coenzyme A and is  catalyzed  by  acyl-CoA
synthase.  In M. bovis  BCG one Acyl-CoA synthase (BCG1721)  (Rv1683)  has been identi‐
fied to be exclusively bound to lipid bodies. Nonreplicating mycobacteria, which overex‐
press  a  BCG1721  construct  with  an  inactive  lipase  domain  displayed  a  phenotype  of
attenuated TAG breakdown and regrowth upon resuscitation. These results indicate that
the gene might be essential for TAG hydrolysis and growth [69].
Together with malate synthase, isocitrate lyase (ICL) is the key enzyme of the glyoxylate cycle
that catalyzes the cleavage of isocitrate to glyoxylate and succinate [81,83]. The M. tuberculo‐
sis genome codes for two isocitrate lyases, icl and icl2, which are essential for the fatty acid
metabolism and jointly required for in vivo growth and virulence. Disruption of icl has only
little effect on survival in macrophages and bacterial loads in lungs of infected mice. Only
disruption of both lyase genes results in a fast elimination of bacteria from lungs of infected
mice and infected macrophages [79,80]. These results strongly suggest that both icl genes are
required for mycobacterial persistence.
All enzymes involved in lipid metabolism in lipid bodies are summarized in Table 1.
M. leprae has approximately one-third as many potential fad enzymes with probable roles
in the β-oxidation. Even though M. leprae genome contains less necessary β-oxidation cy‐
cle  genes than M. tuberculosis,  transcript  analysis  revealed expression of  acyl-CoA meta‐
bolic enzymes including echA1 (ML0120, putative enoyl-CoA hydratase), echA12 (ML1241,
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possible  enoyl-CoA  hydratase),  fadA2  (ML2564,  acetyl-CoA-acetyltransferase),  fadB2
(ML2461,  3-hydroxyacyl-CoA  dehydrogenase),  fadD19  (ML0352,  acyl-CoA  synthase),
fadD26 (ML2358, fatty acid-CoA-ligase), fadD29 (ML0132, probable fatty-acid-CoA synthe‐
tase), fadD28 (ML0138, possible fatty-acid-CoA synthetase), fadE25 (ML0737, probable acyl-
CoA  dehydrogenase)  and  fadE5  (ML2563,  acyl-CoA  dehydrogenase)  [59,60].  This  gives
strong evidence that host lipids provide the main carbon and energy sources for M. lep‐
rae during infection.
The M. leprae genome contains a gene, coding for an isocitrate lyase, aceA. The amino acid-
sequence of AceA (ML1985c) shows 80 % identity with its homologue from M. tuberculosis
ICL2 (Rv1915/1916). AceA is upregulated in both M. leprae-infected nude mouse and human
lesions. [59]. A second icl gene, as observed in M. tuberculosis, is not present in the genome of
M. leprae. This finding is of particular interest, because both lyases, icl and icl2, are jointly
required for in vivo growth and virulence [79,80]. Deletion of icl1 or icl2 has little effect on
bacterial growth in macrophages [80]. So far the M. leprae AceA might play a slightly different
role in as the both isocitrate lyases in M. tuberculosis.
4. Lipid composition in M. leprae infected cells
In 1863, Virchow described foamy cells, which form droplets and surround M. leprae within
the phagolysomes. [84,85]. This lipid capsule forms a characteristic electron-transparent zone.
In contrast to M. tuberculosis, the presence of lipid bodies seem to be rather exceptional in M.
leprae [85]. The lipid capsule contains mycoserosoic acids of phthiocerol dimycocerosates as
well as phenolic glycolipids [86,87]. Brennan reported the full characterization of three phenol-
phthiocerol triglycosides by M. leprae [84]. It has been postulated that many of these molecules
together with phosphatidylinositol mannosides and phospholipids are released from the cell
wall after synthesis, forming the capsule-like region [11]. The dominant lipid in the cell wall
which gives M. leprae immunological specificity is phenolic glycolipid-1 (PGL-1). Phenolic
glycolipid 1 has been isolated in relatively high concentrations from purified bacteria and from
M. leprae infected tissues [88]. PGL-1 is thought to be a major component of the capsule in M.
leprae and constitutes an important interface between bacteria and host [89]. It has been
suggested that PGL-1 is involved in the interaction of M. leprae with the laminin of Schwann
cells, thus PGL-1 hight play a role in peripheral nerve-bacillus interactions [90]. Moreover,
phenolic glycolipids seem to be involved in the in the stimulation of suppressor T-cells in
lepromatous leprosy [91]. Recently it was reported that also LDs from M. leprae infected SCs
and macrophages accumulate mainly host derived lipids, such as oxidized phospholipids [92].
BODIPY stains infected SCs, indicating that LDs contain neutral lipids, such as triacylglycerols
(TAG), but it seems as M. leprae-infected cells accumulate large amounts of cholesterol and
choesterol esters [10].
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Gene Protein
DGAT activity
(in vitro)
Lipid body
associated
Influence on lipid bodies /
TGA accumulation
Modulation of
virulence
M. leprae
homologue
Reference
Rv3130c (tgs1) DGAT + +
Δtgs1
decreases TAG accumulation
NA ML1244 [46,48,68]
Rv3734c (tgs2) DGAT + + NA NA ML1244 [48,68]
Rv3234c (tgs3) DGAT + NA NA NA ML1244 [48,68]
Rv3088 (tgs4) DGAT + NA NA NA ML1244 [48,68]
Rv1760 DGAT + NA NA NA ML1244 [48,68]
Rv2285 DGAT + NA NA NA ML1244 [48,68]
Rv3804c (85A) DGAT + NA
Overexpression increases
production of lipid bodies
NA ML0097 (85A) [71]
BCG1489c [Rv1428c] DGAT NA +
ΔBCG1489c reduces TAG
accumulation
NA ML2427c [69]
BCG3153c (tgs1)
[Rv3130c]
DGAT NA +
ΔBCG3153c reduces TAG
accumulation
NA ML1244 [69]
BCG3794c (tgs2)
[Rv3734c]
DGAT NA +
ΔBCG3794c reduces TAG
accumulation
NA ML1244 [69]
BCG1489c [Rv1428c] acyltransferase NA +
ΔRv1428c reduces TAG
accumulation
NA [69]
Gene Protein
TGA-
hydrolyzing
activity (in vitro)
Lipid body
associated
Influence on lipid bodies /
TGA accumulation
Modulation of
virulence
M. leprae
homologue
Reference
Rv3097c (lipY) Lipase/esterase + NA
ΔlipY reduces TAG hydrolysis.
Overexpression increases TAG
hydrolysis
Overexpression
increases virulence in
mice
ML0314c (lipU)
ML1053
ML1183c
[47]
Rv1399c (lipH ) Lipase/esterase + NA NA NA ML0314c (lipU) [72]
BCG1721 [Rv1683] Lipase/esterase + (in vivo*) + + (*) NA ML1346 [69]
Rv0183 Lipase/esterase
Hydrolyzes only
monoacylglyceri
des
NA NA NA ML2603 [76]
Rv2224c Lipase/esterase NA NA NA
Gene disruption
decreases virulence in
mice
ML1633c [77]
Gene Protein
Isocitrate
cleavage (in
vitro)
Lipid body
associated
Influence on lipid bodies /
TGA accumulation
Modulation of
virulence
M. leprae
homologue
Reference
Rv0467 (icl),
Rv1915-1916 (icl2)
isocitrate lyase + NA NA
The Δicl , Δicl2 strain
shows no intracellular
replication
ML1985c (aceA) [79,80,93-95]
Table 1. Enzymes involved in lipid body metabolism in M. tuberculosis and M. bovis BCG. Homologous genes in M.
tuberculosis H37Rv are written in square brackets. NA, not applicable. *, expressed in yeast as recombinant protein.
DGAT, diacylglycerol acyltransferase
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5. Induction of lipid droplet biogenesis
Since the biogenesis of lipid droplets in macrophages seems an absolute requirement for
intracellular bacteria to establish infections, we will discuss mechanisms involved in foam cell
formation and development of lipid droplets.
5.1. Scavenger receptor mediated lipid droplet biogenesis in M. tuberculosis
Upon infection with pathogenic bacteria macrophages generate reactive oxygen species (ROS).
The release of ROS generates oxidative stress, and results not only in damage to cellular
structures but also to oxidation of fatty acids, such as low density lipoproteins (OxLDL) in
granulomas. The binding of OxLDL to type 1 scavenger receptors CD36 and LOX1 induces
increased surface expression of both receptors, leading to uptake of OxLDL [96-98]. In addition,
CD36 increases the uptake of M. tuberculosis by macrophages [99]. The increased rate of OxLDL
uptake results in the accumulation of oxidized lipids, which finally leads to the formation of
foamy macrophages [98]. M. tuberculosis and M. leprae benefit from the accumulated OxLDL
in the infected macrophage. OxLDL-laden lung macrophages show enhanced replication of
intracellular M. tuberculosis compared to macrophages loaded with non-oxidized LDL [98].
The presence of oxidized phospholipids in M. leprae infected macrophages down-regulates the
innate immune response and contributes to pathogenesis [92]. Moreover, scavenger receptor-
deficient phagocytes are characterized by a reduced intracellular bacterial survival and a lower
cytokine response [100].
5.2. TLR mediated LD formation in M. bovis and M. leprae
Mycobacterium bovis Bacillus Calmette-Guérin (BCG) and M. leprae are recognised by the Toll-
like receptors (TLR) TLR6 and TLR2 [101,102]. Mycobacterium bovis Bacillus Calmette-Guérin
induced lipid body formation is TLR2 mediated [103]. The mycobacterial surface molecule
lipoarabinomannan (LAM) induces the formation of foamy macrophages by binding to TLR2
[104] (Figure 3).
M. leprae association to macrophages is mediated by binding of the bacteria to TLR2 and TLR6.
Heterodimerization of TLR2 and TLR6 leads to downstream signalling and subsequent LD
formation [102,105]. Macrophage association is not dependent on binding to TLR2 or TLR6.
Neither a TLR2-/- or TLR6-/- knockout macrophage shows reduced binding to M. leprae. This
suggests that both TLR2 and TLR6 can bind M. leprae alone, or/and the presence of other
receptors, binding to M. leprae. The TLR2-/- or TLR6-/- knockout macrophages do also not
completely abolish LD formation, but show only reduced LD formation [102]. This suggests
the presence of additional signalling pathways for LD formation. In SCs TLR6, but not TLR2,
is essential for M. leprae-induced LD biogenesis in [101]. In LL lesions, accumulated with LD
enriched macropages the genes for ADRP and CD36 are up-regulated [30,92,102]. This suggests
also an involvement of CD36 in LD formation of M. leprae (Figure 4) [99].
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Figure 3. Induction of lipid droplet biogenesis in macrophages by Mycobacterium tuberculosis. 1) Recognition of bac‐
teria by Toll-like receptors (TLR) trigger phagocytosis and subsequent formation of lipid droplets. 2) The infected mac‐
rophage produces reactive oxygen species (ROS), which oxidize LDL. 3) The binding of OxLDL to type 1 scavenger
receptors CD36 and LOX1 induces increased surface expression of both receptors and increases uptake of host´s oxi‐
dized fatty acids. 4) Mycobacterium-laden phagosomes internalize lipid droplets. 5) Within the lipid droplets the bac‐
teria form lipid bodies and finally enter the dormant state. ApoB-100, apolipoprotein B-100.
Figure 4. Basic mechanisms of lipid droplet induction in M. leprae infected macrophages. M. leprae attaches to TLR2
and TLR6. Heterodimerization of TLR2 and TLR6 induces downstream signalling and subsequent accumulation by LD
formation. [102,105]. In SCs TLR6, but not TLR2, is essential for M. leprae-induced LD biogenesis [101]. Cholesterol
from the LDs accumulates at the site of mycobacterial entry and promotes mycobacterial uptake. Cholesterol also re‐
cruits TACO from the plasma membrane to the phagosome [61]. TACO prevents phagosome-lysosome fusion and pro‐
motes intracellular survival [62,63]. Hypothetical uptake of oxidized lipids by scavenger receptors in M. leprae:
Reactive oxygen species might oxidize low-density lipoprotein (LDL) to oxLDL, which is thought to be subsequently
bound and taken up by scavenger receptors CD36 and LOX1. CHO, cholesterol. Unknown mechanisms for LD induc‐
tion are indicated with a question mark.
5.3. Mycolic acids induce the formation of foamy macrophages
Mycolic  acids  and  oxygenated  mycolic  acids  are  strong  inducers  of  monocyte-derived
macrophages differentiation into foamy macrophages [19,106]. Peyron et al. demonstrated
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that that a set of oxygenated mycolic acids specifically produced by highly virulent myco‐
bacteria  species  (M. tuberculosis,  M. avium)  were responsible  for  the formation of  foamy
macrophages [19].
6. Clinical implications
Several enzymes of the mycobacterial lipid-biosynthesis are regarded as targets for new
antitubercular compounds. The research focused on enzymes, involved in the biosynthesis of
lipid compounds of the mycobacterial cell wall [107]. Especially the biosynthesis of the highly
toxic cord factor is an attractive target. The cord factor is synthesized by the antigen 85 complex
[108,109]. It was recently shown that one member of the complex, antigen 85A is involved in
the formation of intracellular lipid bodies [71]. Antigen 85 is an important virulence factor. It
has been shown that M. tuberculosis requires the expression of Ag85A for growth in macro‐
phages [110]. M. tuberculosis strain lacking Ag85C shows an decrease of 40% in the amount of
cell wall linked mycolic acids [111,112]. The treatment by a trehalose analogue, 6-azido-6-
deoxy-α,α'-trehalose (ADT) inhibits the activity of all members of Ag85 complex in vitro [108,
113]. Also ethambutol targets the synthesis of arabinogalactan, isoniazid and ethionamide
inhibit biosynthesis of mycolic acids [107].
The most potent inhibitor for mycolic acid biosynthesis is isoniazid (INH). INH is a prodrug
which is converted to the isonicotinoyl radical by KatG. INH forms a covalent adduct with
NAD. This INH-NAD adduct inhibits FAS-II enoyl-ACP reductase InhA, which in conse‐
quence leads to inhibition of mycolic acid biosynthesis, and ultimately to cell death [114-117].
The inhibitors of fatty acid biosynthesis are summarized in Figure 2 and Table 2.
Synthesis step Enzyme Compound / class References
FAS-I and
FAS-II
KasA/KasB Cerulenin (2R,3S-epoxy-4-oxo-7,10-trans,trans-
dodecanoic acid amide
[118] [119]
FAS-II KasA/KasB TLM (Thiolactomycin) [120-122]
FAS-II KasA/KasB Platensimycin [123]
InhA INH (Isoniazid) [124]
InhA ETH (Ethionamide) [125]
InhA TRC (Triclosan) [126]
InhA alkyl diphenyl ethers (Triclosan derivatives) [127]
InhA 2-(o-Tolyloxy)-5-hexylphenol (PT70) [120]
Cyclopro-panation CMASs (cmaA2, mmaA2 or
pcaA)
TAC (Thiacetazone) [128]
MmaA4 TAC (Thiacetazone) [128]
Table 2. Inhibitors of fatty acid biosynthesis
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7. Conclusion
The formation of lipid inclusions during infection in the host as well as in the pathogen during
intracellular infection with M. tuberculosis and M. leprae plays an important role in pathogen‐
esis. A hallmark of intracellular infection is the formation of foamy macrophages. M. tubercu‐
losis and M. leprae induce the formation of lipid droplets in the host cell. The accumulated lipids
are used as energy and carbon source. In fact M. tuberculosis seems to switch completely to
fatty acid catabolism at the transition from the acute to the chronic phase of infection. The
central role of fatty acid metabolism during the dormant state of M. tuberculosis is underlined
by the finding that both isocitrate lyase, icl and icl2, are essential for intracellular replication
in the lung [79,80]. The TAG metabolism and the resulting formation of lipid inclusions of host
and pathogen play a fundamental role in infection. Indeed TAG-derived fatty acids from the
host cell are imported into M. tuberculosis and incorporated into bacterial TAG [46]. In
conclusion the enzymes involved in lipid droplet metabolism are essential for survival of the
pathogen in the lung and thus attractive targets for novel drugs. Especially enzymes with
DGAT activity such as Tgs and Ag85A seem to be promising drug target candidates. Another
promising targets seem to be the recently discovered cell wall associated and secreted
esterases, which are involved in the utilization of host cell lipids such as Rv0183 and LipY [55,
75,76]. Future studies should also focus on the lipid metabolism of M. leprae, an organism which
upregulates several genes of the host´s lipid metabolism during infection [92]. The regulation
of lipid droplet formation in the host cell is another important topic. Recent sudies revealed
that intracellular pathogens induce the expression of LDL receptor and scavenger receptors
CD36 and LOX1 for the internalization of native and oxidized fatty acids. Especially the
generation of oxidized lipids by macrophage-derived reactive oxygen species seems to be an
important mechanism for the induction of scavenger receptors.
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